Pelthos Therapeutics has announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York. This event offers an opportunity for investors to learn more about the company’s innovative therapeutic products aimed at addressing unmet medical needs, particularly in the area of cutaneous infectious diseases.

For those interested in health and wellness, Pelthos is making strides with its lead product, ZELSUVMI® (berdazimer) topical gel, which is the first prescription treatment approved for home use to manage molluscum contagiosum, a common skin infection. This means that patients can now treat this condition more conveniently, potentially leading to better adherence to treatment and improved health outcomes. The company also offers other topical treatments for conditions like impetigo and head lice, highlighting its commitment to providing effective solutions for everyday health issues.

Currently, Pelthos is a commercial-stage biopharmaceutical company, which means it is actively selling its products and working to expand its portfolio. While the information shared at the conference may be of interest to investors, it also reflects the ongoing development of treatments that could benefit many people dealing with skin infections.

As Pelthos continues to innovate in the field of dermatological treatments, it’s worth keeping an eye on how their products can improve the quality of life for those affected by these conditions.

Source: globenewswire.com